The Impact Trips and Free Trade Agreements Have on Access to Medicines: The Cases of Canada and Colombia
Consuelo Ahumada
Abstract
Consuelo Ahumada
Abstract
Consuelo Ahumada's article, Impact TRIPS and Free Trade Agreements have on Access to Medicines: The Cases of Canada and Colombia, discusses the consequences of American international trade strategies with regard to the pharmaceutical industry and national healthcare systems. Her article shows how successive rounds of international trade negotiations and bilateral free trade agreements have served to strengthen the intellectual property rights of multinational pharmaceutical companies. As Ahumada amply demonstrates, one of the outcomes of enhanced intellectual property regimes is that they have served to restrict access to medicines and have negatively affected the delivery of health care in Canada and Colombia.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Consuelo Ahumada's article, Impact TRIPS and Free Trade Agreements have on Access to Medicines: The Cases of Canada and Colombia, discusses the consequences of American international trade strategies with regard to the pharmaceutical industry and national healthcare systems. Her article shows how successive rounds of international trade negotiations and bilateral free trade agreements have served to strengthen the intellectual property rights of multinational pharmaceutical companies. As Ahumada amply demonstrates, one of the outcomes of enhanced intellectual property regimes is that they have served to restrict access to medicines and have negatively affected the delivery of health care in Canada and Colombia.
Key concepts: TRIPS architecture, Access to medicines, Free trade, Free trade agreement, Free access, Business, International trade, TRIPS Agreement